Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
viernes, 28 de agosto de 2026
Clinical Trial Updates in Secondary Stroke Prevention CME COEX Convention & Exhibition Center Thursday, 22 October 2026 | 12:00 - 13:00 KST
https://events.medscapelive.org/website/98699/?utm_campaign=edu_cardio%2Fneuro_457370.11a_regpage&utm_source=edu&utm_theraputic_area=1900&utm_medium=em&utm_content=int
Secondary stroke is a global challenge, with 1 in 4 people experiencing a recurrent stroke even with the treatment advances that have been made to date. In this dynamic and informative symposium, international stroke experts will take us through the latest advances in secondary stroke prevention and the most recent data on factor XIa inhibitors. They will provide their perspectives on what the data may mean for treating patients and how it might be implemented into future clinical practice.
Does Mental Health Drive Fatigue Years After Breast Cancer Treatment? Damian McNamara, MA
https://www.medscape.com/viewarticle/does-mental-health-drive-fatigue-years-after-breast-cancer-2026a1000tpo?ecd=WNL_trdalrt_pos1_ous_260828_etid8639743&uac=148436CN&impID=8639743
A new multicenter study shows women who receive treatment for breast cancer can face long-term, intractable fatigue years after improvement or resolution of chemotherapy-related cardiac dysfunction or anemia.
Key Decisions. Complex Cases. Better Systemic Mastocytosis Care New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm C
https://na.eventscloud.com/website/98569/
Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Join us for this interactive 90-minute CME/CE symposium featuring livestreaming and social media simulcast. Expert faculty will examine critical clinical turning points to overcome inertia and uncertainty, optimizing treatment decisions—particularly when considering escalation to disease-directed therapy. Walk away with practical strategies to evaluate disease control, integrate emerging clinical evidence, and optimize management across the SM continuum.
Attend In-Person
https://na.eventscloud.com/website/98569/
Researchers Have Created A Molecular Map Of Autism In The Brain
Researchers Have Created A Molecular Map Of Autism In The Brain
The research, released Thursday in the journal Science, is a map of the genetic mutations associated with autism and how they affect the brain. Scientists hope to use this map to develop more targeted therapies.
https://kffhealthnews.org/morning-briefing/friday-august-28-2026/
The Butterfly Effect: How Kids Can Help Save Pollinators By Ivanhoe Broadcast News on September 11, 2025
The Butterfly Effect: How Kids Can Help Save Pollinators
By Ivanhoe Broadcast News on September 11, 2025
GAINESVILLE, Fla. (Ivanhoe Newswire) — Butterflies aren’t just beautiful, they’re essential to our ecosystem and our food supply. New data reveals the U.S. butterfly population has plunged by 22% in just two decades. But there’s hope, and a role parents and kids can play in turning the tide.
https://www.ivanhoe.com/positive-parenting/the-butterfly-effect-how-kids-can-help-save-pollinators/
274 Reasons to Live! By Ivanhoe Broadcast News on September 4, 2026
274 Reasons to Live!
By Ivanhoe Broadcast News on September 4, 2026
Denver, Colo. (Ivanhoe Newswire) — Every two seconds, someone in the U.S. needs blood. Whether it’s a car crash, cancer treatment, major surgery or a natural disaster, donated blood saves millions of lives each year. And the American Red Cross reports we are currently in a chronic blood supply shortage. Ivanhoe introduces us to one man who survived against nearly impossible odds. And he survived because hundreds of people took the time to donate.
https://www.ivanhoe.com/?p=37544&preview=1&_ppp=760ca10791
Scan For Life: Spotting Ascending Aortic Aneurysms By Ivanhoe Broadcast News on September 3, 2026
Scan For Life: Spotting Ascending Aortic Aneurysms
By Ivanhoe Broadcast News on September 3, 2026
DENVER, Colo. (Ivanhoe Newswire) — Many people assume that if they feel healthy, they are healthy. But some of the most dangerous heart conditions grow silently, without pain, without symptoms, and without warning. One man’s experience is a reminder that sometimes the biggest health threats are the ones you never feel.
https://www.ivanhoe.com/?p=37538&preview=1&_ppp=0bcdf21e61
Trapped: Saving Nic’s Hand By Ivanhoe Broadcast News on September 2, 2026
Trapped: Saving Nic’s Hand
By Ivanhoe Broadcast News on September 2, 2026
DENVER, Colo. (Ivanhoe Newswire) — When a traumatic injury happens, every minute counts. But nearly 30 million Americans, about 12 percent of the population, live more than an hour from a level one or level two trauma center. For one firefighter-paramedic, getting to the right specialist in time helped save not only his hand, but his career.
https://www.ivanhoe.com/?p=37535&preview=1&_ppp=1d9765d6a5
I’m Fine! The Men Who Don’t Look Depressed By Ivanhoe Broadcast News on September 1, 2026
I’m Fine! The Men Who Don’t Look Depressed
By Ivanhoe Broadcast News on September 1, 2026
ORLANDO, Fla. (Ivanhoe Newswire) — September is Suicide Prevention Month. And while more than 21 million American adults experience a major depressive episode each year, experts say depression in men is often missed because it doesn’t always look the way people expect. Ivanhoe explains why recognizing often overlooked signs could save a life.
https://www.ivanhoe.com/?p=37532&preview=1&_ppp=712dff537a
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults?utm_medium=email&utm_source=govdelivery
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib), for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya offers patients an important new alternative, providing an efficacious oral treatment with an acceptable risk profile.
Lisraya is a once-daily pill that works by blocking certain proteins in the body, called Janus kinases, that become overactive in people with dermatomyositis. In a 52-week phase 3 clinical trial, patients treated with Lisraya achieved statistically significant and clinically meaningful improvements in disease activity compared to placebo and were more likely to reduce their corticosteroid use. Lisraya carries a boxed warning for serious infections, increased all-cause mortality, malignancy, major adverse cardiovascular events, and thrombosis.
The approval was granted to Priovant Therapeutics, Inc.
FDA approves first RAS-targeting drug for pancreatic cancer Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week. Brought to you byDDN editorial team
FDA approves first RAS-targeting drug for pancreatic cancer
Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week.
Brought to you byDDN editorial team
https://www.drugdiscoverynews.com/fda-approves-first-ras-targeting-drug-for-pancreatic-cancer-17485?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9EN7tTjw5AACeTGXWzPG4sDAiI85wpUoJKN4OTl_1AX3HxIVf1wN5dhIICRGkrBf51M-YObbPiQ4ZcD-lKgdhIBhI0YA&_hsmi=435662457&utm_content=435662457&utm_source=hs_email
The FDA has approved Revolution Medicines’ Rasonque (daraxonrasib) for adults with advanced pancreatic adenocarcinoma, marking the first approved therapy designed to directly target a genetic driver of the disease. The once-daily oral RAS inhibitor is approved for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are not candidates for multiagent treatment. In a randomized Phase 3 trial involving 500 previously treated patients, Rasonque more than doubled median overall survival compared with standard chemotherapy, extending it to 13.2 months versus 6.7 months. Although pancreatic cancer accounts for only around three percent of cancer diagnoses in the US, it is responsible for approximately eight percent of cancer deaths, with more than 50,000 people dying from the disease each year. Rasonque targets RAS proteins, which drive tumor growth in most pancreatic adenocarcinomas, and was granted Breakthrough Therapy, Orphan Drug, and Priority Review designations. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,” said Angelo de Claro, Director of the FDA’s Oncology Center of Excellence, in the press release. – Bree Foster
Vaccine generates durable immune responses in people at high risk for pancreatic cancer
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
Written byAndrea Corona
https://www.drugdiscoverynews.com/vaccine-generates-durable-immune-responses-in-people-at-high-risk-for-pancreatic-cancer-17365?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--pnyxMGe4WAmR10-eoCMRh93eZQLfg3OPd8-KLR0fQsdXhnDun7SfqooNgC2XR93XpO02KIVzpc-FrXiN2XQtje5GAkA&_hsmi=435662457&utm_content=435662457&utm_source=hs_email
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest five-year survival rates of any cancer, in large part because it is rarely caught early. Most cases are diagnosed at advanced stages, when surgery is no longer an option and systemic treatment options remain limited. For the roughly 10 percent of cases driven by hereditary predisposition, high-risk individuals are currently managed through surveillance — watching and waiting for signs of transformation into cancer with few tools to intervene before that happens.
Sensitive blood test detects pancreatic cancer recurrence early
A new blood test focusing on KRAS mutations found evidence of pancreatic cancer recurrence before standard testing.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/sensitive-blood-test-detects-pancreatic-cancer-recurrence-early-17363?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_lEMOQ7z1LlGY2i-xtI9X4cKak_NmlpcljWclYsgkVaaFBg8M90rWJOw-McHTb-fQEtuqX6PJO0JPOpALCW_GpCLMkeQ&_hsmi=435662457&utm_content=435662457&utm_source=hs_email
Pancreatic cancer almost always comes back. Although the last few years have seen major advances in treatments for this highly fatal cancer, most patients will experience recurrence because today’s standard testing cannot detect lingering microscopic cancer cells.
jueves, 27 de agosto de 2026
Breast milk fats may reflect more than the fats a mother eats
https://www.news-medical.net/news/20260826/Breast-milk-fats-may-reflect-more-than-the-fats-a-mother-eats.aspx
From dietary fats to vitamins and minerals, researchers mapped how a mother’s nutritional intake relates to the complex fatty acid composition of her milk.
A recent cross-sectional study published in the European Journal of Nutrition found that higher maternal intakes of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and trans fatty acids were associated with higher proportions of the corresponding fatty acids in breast milk.
From National Leadership to European Action, an Irish Presidency of the EU Associated Event – September 15, Dublin
The European Sepsis Alliance is honoured to invite you to “Making sepsis a European health policy priority: from national leadership to European action”, taking place at the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, in Dublin on 15 September. The event is an Associated Event of the Irish Presidency of the Council of the European Union. It is co-hosted by the Global Sepsis Alliance and the Irish Sepsis Alliance.
This afternoon conference will bring together top leaders of the European academic and clinical space alongside high-level representatives of national and European institutions, including the European Commission, WHO Europe, and the Irish government, with the possible participation of Minister of Health, Jennifer Carroll McNeill. Confirmed speakers include Dr. Mariam Jashi, CEO of the Global Sepsis Alliance and former Deputy Minister of Health of Georgia, ESA Chair Prof. Evangelos J. Giamarellos-Bourboulis, Prof. Mary Horgan, Chief Medical Officer of Ireland, Minister of State Niamh Smyth, and the National Sepsis Coordinator for Belgium, Tom Vanacker. Patient advocates, sepsis survivors, and representatives of countries with established national sepsis strategies — including Ireland, France, the United Kingdom, Belgium, and Sweden — will contribute to dedicated panels.
https://www.europeansepsisalliance.org/news/2026/8/18/from-national-leadership-to-european-action-an-irish-presidency-of-the-eu-associated-event-september-15-dublin
The central objective of the Dublin conference is to trigger a collective call on the European Commission and Council to develop a coordinated European framework for sepsis — building on the ESA's Call to Action launched at the European Parliament in March 2025, subsequently endorsed by WHO Europe Regional Director Dr. Hans Kluge, and renewed at the 9th ESA Annual Meeting in Brussels in March 2026 with the support of MEPs Vytenis Andriukaitis and Sirpa Pietikäinen.
The event will be livestreamed on YouTube. In-person places are limited. Whether you are joining us in Dublin or online, we hope you will be part of this important step in the European sepsis advocacy journey.
For any questions, please contact: Simone Mancini, Director, European Sepsis Alliance — Simone.Mancini@global-sepsis-alliance.org
https://www.europeansepsisalliance.org/news/2025/3/19/esa-launches-call-to-action-for-eu-institutions-and-member-states-at-the-european-parliament?rq=call%20to%20action
Radiation in Pancreatic Cancer: ASTRO Updates Its Guidance Megan Brooks ++
https://www.medscape.com/viewarticle/radiation-pancreatic-cancer-astro-updates-its-guidance-2026a1000tt6
Updated guidance from the American Society for Radiation Oncology (ASTRO) gives radiation therapy a more clearly defined and, in some cases, broader role in pancreatic cancer, reflecting both new clinical trial data and advances that allow clinicians to deliver radiation more precisely while protecting nearby organs.
Adding Radiotherapy to NAC Shows No Survival Benefit in PDAC
Edited by Amy Norton
https://www.medscape.com/viewarticle/adding-radiotherapy-nac-shows-no-survival-benefit-pdac-2026a1000ttk?src=
In a retrospective cohort study, patients with pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant chemotherapy (NAC) plus radiotherapy showed improved pathological response compared with those who received NAC alone. But their recurrence rates and overall survival were no better.
What Is Fibermaxxing and Is More Fiber Always Better? Wolfgang Paik
https://www.medscape.com/viewarticle/what-fibermaxxing-and-more-fiber-always-better-2026a1000ttx?src=
“Fibermaxxing” has emerged as a popular nutrition trend on social media, with influencers encouraging individuals to maximize their fiber intake through legumes, whole grains, vegetables, fruits, seeds, and psyllium husk. Although higher-fiber intake is associated with several health benefits, more fiber is not necessarily better. Very high-fiber intake can cause gastrointestinal symptoms and has not been shown to provide proportionately greater benefits.
Will the new UN political declaration deliver? The Lancet HIV + +... + +
Will the new UN political declaration deliver?
The Lancet HIV
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00205-5/fulltext?dgcid=raven_jbs_etoc_email
Sep 2026
Volume 13Number 9e611-e678
https://www.thelancet.com/journals/lanhiv/issue/vol13no9/PIIS2352-3018(26)X2008-2
Cost-effectiveness of emergency department opt-out testing for HIV in England: a modelling study
Josephine G Walker, PhDa,b Send email to josephine.walker@bristol.ac.uk ∙ Rebecca F Baggaley, PhDc,d,e ∙ Gareth Myring, MSca,f ∙ Michael A Irvine, PhDg ∙ Asra Asgharzadeh, PhDa ∙ Yoko V Laurence, PhDa,b ∙ et al
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00109-8/fulltext?dgcid=raven_jbs_etoc_feature_lanhiv
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial
Prof Linda-Gail Bekker, PhDa Send email to linda-gail.bekker@hiv-research.org.za ∙ Dhayendre Moodley, PhDb ∙ Dazon Dixon Diallo, MPHc ∙ Ishana Harkoo, MBChBb ∙ Godfrey Kigozi, MPHd ∙ Noah Kiwanuka, PhDe ∙ et al.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00112-8/abstract?dgcid=raven_jbs_etoc_feature_lanhiv
Optimizing Clinical Practice in Prostate Cancer
https://www.medscape.org/advances/optimizing-clinical-practice-prostate-cancer-2026a1000jj9?src=mkmcmr_driv_32025_mscpedu_461680.01_ace_launch&uac=148436CN
Advanced prostate cancer (PC) includes metastatic hormone-sensitive PC (mHSPC), nonmetastatic castration-resistant PC (nmCRPC), and metastatic castration-resistant PC (mCRPC). Management of these disease types differs, but the overall goal when treating...
Slowing the progression of juvenile-onset ALS
In some cases, the diseases being studied by the Oxford-Harrington Rare Disease Centre are so rare that they have yet to be identified and named. Although they may be nameless, they are never faceless: behind each disease or cluster of symptoms is a patient and their family hoping for a treatment or, better yet, a cure
https://rarerevolutionmagazine.com/slowing-the-progression-of-juvenile-onset-als/
A rare disease and a difficult life
Bonnie Mattingly Woolston knows all too well what it’s like to live with a rare disease. Like her father, grandfather and generations of Mattingly ancestors, Bonnie had suffered throughout her life from an unidentified progressive motor neuronopathy.
An early memory of Bonnie’s came when she was six years old. Standing on the front porch of their home and watching her father struggle to walk across the lawn without falling, Bonnie asked her mother: “Mama, how did Daddy hurt his legs?” The reply: “Hush, honey. Daddy doesn’t like to talk about it.”
As Bonnie relates: “So I hushed. I stayed hushed a few months later when our gym teacher had us run races on the playground and I was always last. I stayed hushed in high school when I sought out the least travelled staircase to reach my second-storey classes because I held up the hordes of students using the main stairs. The same was true at my college dorm, where four floors separated my bedroom from the dining room. And, in my first apartments after college, which were invariably two or three storeys above ground. I hated stairs.”
Making Travel Accessible: SMAshing My Limits Partners With Becoming rentABLE by Madaline Spencer| Published on: Aug 27, 2026
Making Travel Accessible: SMAshing My Limits Partners With Becoming rentABLE
by Madaline Spencer| Published on: Aug 27, 2026
Tracey Dawson, PhD, Senior Vice President, US Therapeutic Area Head Neuroscience at Novartis, discusses the collaboration between Novartis, SMAshing My Limits, and Becoming rentABLE, striving to make travel accessible.
https://checkrare.com/making-travel-accessible-smashing-my-limits-partners-with-becoming-rentable/
An old small molecule drug could fight obesity and keep lean muscle First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss. Written byAllison Whitten, PhD
An old small molecule drug could fight obesity and keep lean muscle
First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/an-old-small-molecule-drug-could-fight-obesity-and-keep-lean-muscle-17474
Losing weight can happen via two paths: eating less, or spending more energy. Today’s blockbuster GLP-1 drugs are well-known for their ability to help people eat less, but finding drugs that increase energy expenditure could add another effective option to treat obesity and related metabolic disorders.
Rejuvenating exhausted T cells improves immunotherapy for myeloma Researchers showed that an oral medication can activate worn-out T cells. Written byAllison Whitten, PhD
Rejuvenating exhausted T cells improves immunotherapy for myeloma
Researchers showed that an oral medication can activate worn-out T cells.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/rejuvenating-exhausted-t-cells-improves-immunotherapy-for-myeloma-17305?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8sXZKOsFWOR1uMbxyadJfb1SMDkNtZUcgKBaoqNnJplsUfF43HZpW8isrnCg6i-sBd_C_E50hJdJgK5FUR5fyau6_zHw&_hsmi=435454106&utm_content=435454105&utm_source=hs_email
CAR T cell therapies have seen rapid success in treating blood cancers, yet most patients will relapse months or years later. That can be due to “exhausted” T cells that are no longer able to fight off cancer cells.
Turning tumor macrophages from foes into allies A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance. Written byBree Foster, PhD
Turning tumor macrophages from foes into allies
A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/turning-tumor-macrophages-from-foes-into-allies-16970?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-92kdmX5amh13rjC4pji3KtCxF3s0ySfyMh80OsJ5YGvDNhhX3FEWPypY2aqRByUYKkuRNSmEKYKRzvyG5mrTU70qCHEA&_hsmi=435454106&utm_content=435454105&utm_source=hs_email
Cancer immunotherapy has transformed oncology by harnessing the immune system to recognize and destroy tumors. Approaches such as immune checkpoint inhibitors and engineered immune cells have delivered durable responses in some patients — and nowhere more dramatically than CAR-T cell therapies in blood cancers. Several CAR-T treatments are now FDA-approved and have produced long-term remissions in leukemia and lymphoma.
Brii Biosciences inches closer to functional cure for hepatitis B but future is uncertain New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then. Written byAllison Whitten, PhD
Brii Biosciences inches closer to functional cure for hepatitis B but future is uncertain
New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/brii-biosciences-inches-closer-to-functional-cure-for-hepatitis-b-but-future-is-uncertain-17480
The hepatitis B virus (HBV) vaccine is up to 90 percent effective at preventing HBV when given within 24 hours after birth. But for the hundreds of millions of people around the world who have already acquired the viral infection that attacks their liver, there is no cure. Current standard treatments consist of daily, lifelong antiviral therapies where the virus still hides within liver tissue.
Using microbes to fight cancer Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies. Written byBree Foster, PhD
Using microbes to fight cancer
Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/using-microbes-to-fight-cancer-17478
More than 130 years ago, New York surgeon William Coley noticed that some cancer patients experienced tumor regression after developing severe bacterial infections. His observations led him to develop Coley’s toxins, a mixture of killed bacteria intended to stimulate the immune system against cancer.
miércoles, 26 de agosto de 2026
Maternal obesity alters fetal liver metabolism via placental molecular signals
https://www.news-medical.net/news/20260826/Maternal-obesity-alters-fetal-liver-metabolism-via-placental-molecular-signals.aspx
A mother's obesity during pregnancy may send molecular signals across the placenta that permanently alter her son's liver metabolism, according to a new study in mice published in Nature Communications. The research traces this effect to a maternal sEV–miRNA–epigenetic axis that links fetal liver programming to long-term metabolic health.
Gut bacteria may send different biological signals in Parkinson’s disease
https://www.news-medical.net/news/20260826/Gut-bacteria-may-send-different-biological-signals-in-Parkinsone28099s-disease.aspx
A new study from the University of Oulu suggests that gut bacteria may send different biological signals in Parkinson’s disease. The findings add to growing evidence that changes in the gut could be linked to Parkinson’s disease and may eventually help researchers identify new underlying mechanisms for the condition.
Study tracks global patterns and socioeconomic inequalities in the burden of breast cancer
https://www.news-medical.net/news/20260826/Study-tracks-global-patterns-and-socioeconomic-inequalities-in-the-burden-of-breast-cancer.aspx
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among women globally, accounting for nearly 2.3 million new cases and 670,000 deaths in 2022 alone. While traditional metrics like annual incidence rates provide a snapshot of disease burden, they do not capture the cumulative probability that an individual will face breast cancer over their entire lifetime. Moreover, the interplay of reproductive patterns, lifestyle factors, screening access, and treatment quality varies enormously across regions with different levels of economic development. Based on these challenges, there is a clear need for a more intuitive, comparable indicator that accounts for life expectancy and competing mortality risks to guide global cancer control strategies
Why living to 100 may depend on far more than diet and exercise
https://www.news-medical.net/news/20260825/Why-living-to-100-may-depend-on-far-more-than-diet-and-exercise.aspx
From diet and exercise to social ties and genetics, researchers examined why the habits linked to healthier aging may not fully explain who survives to 100.
In a recent critical narrative review published in the journal Minerva Medica, researchers synthesized multidisciplinary evidence investigating whether human longevity can be engineered through behavioral modifications and standardized lifestyle “recipes”. The review aimed to assess the scientific validity of the increasingly pervasive commercial and media narrative associating human longevity with lifestyle choices.
Ear Microbiome Composition and Its Role in Health and Disease
https://www.news-medical.net/health/Ear-Microbiome-Composition-and-Its-Role-in-Health-and-Disease.aspx
From protective cerumen and resident microbes to striking shifts in bacterial and fungal communities, emerging sequencing research is uncovering a complex microbial ecosystem within the ear that may reshape our understanding of ear health and disease.
Lasers and Math Can Help Doctors Deliver Just the Right Amount of Medicine August 26, 2026 By: Henry Nonnemaker
https://www.nist.gov/blogs/taking-measure/lasers-and-math-can-help-doctors-deliver-just-right-amount-medicine
When doctors need to deliver precise doses of medicine on a strict schedule, they often administer it intravenously. Intravenous drug delivery methods need to carefully control the flow of medicine into a patient. Knowing the medicine’s flow rate — or the volume of fluid flowing into the patient each second or minute — is crucial to delivering the right amount of medicine at the right time.
Surprisingly, the correct amount is sometimes not very much at all. Imagine a one-liter bottle divided up into a billion parts. One of those parts is a nanoliter.
Doctors may only need a handful of nanoliters of fluid to flow each minute.
Resilience and well-being as positive determinants of mental health in Israel amid challenges Rabab Awad* [1]ORCID iD , Alon Zamir [2,3]ORCID iD , Liat Ayalon [1] + +...
https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8346
The State of Israel, with its unique social fabric, provides a distinctive context for examining resilience and well-being as positive indicators of mental health. Although a growing body of research has addressed these issues, existing knowledge remains fragmented and lacks an integrative, multilevel synthesis. This narrative review synthesizes empirical research conducted in Israel since 2000 on resilience and well-being in the contexts of war and armed conflict, immigration waves, and the COVID-19 pandemic. The review is guided by a multidimensional analytical framework comprising two axes. The first examines resilience and well-being at the macro, meso, and micro levels, emphasizing societal-, institutional-, community-, and individual-level factors that potentially enhance or maintain resilience and well-being in the face of these challenges. The second compares findings across population groups, including ethnic groups, age cohorts, essential workers, and other vulnerable populations in Israeli society. The findings indicate that resilience and well-being vary across the individual, community, and societal levels and across different societal challenges, reflecting the interaction of personal, relational, and structural factors under prolonged stress. Overall, resilience and well-being emerge as key positive dimensions of mental health, highlighting the need for context-sensitive and multilevel approaches to strengthen adaptive functioning during challenging times.
https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav
The far-reaching effects of wildfire smoke The Lancet Respiratory Medicine +... ++
The far-reaching effects of wildfire smoke
The Lancet Respiratory Medicine
https://www.thelancet.com/journals/lanres/issue/vol14no9/PIIS2213-2600(26)X2008-2
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
Prof Zhengbo Song, MDa Send email to songzb@zjcc.org.cn ∙ Prof Xingya Li, MDb ∙ Rongbo Lin, MDc ∙ Huaqiu Shi, BSd ∙ Yuan Yuan, MSce ∙ Ying Liu, MDf ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00142-6/abstract?dgcid=raven_jbs_etoc_feature_lanres
Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
Prof Kate Leslie, MDa,b Send email to kate.leslie@mh.org.au ∙ Jai N Darvall, PhDa,b ∙ Prof Matthew T V Chan, PhDc ∙ Prof Philip J Peyton, PhDa,d ∙ Prof Paul S Myles, DSce,f ∙ Prof Tomás B Corcoran, MDg ∙ et al
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00158-X/fulltext?dgcid=raven_jbs_etoc_feature_lanres
Oculomics and the search for brain biomarkers The Lancet Digital Health +... ++
Oculomics and the search for brain biomarkers
The Lancet Digital Health
https://www.thelancet.com/journals/landig/issue/vol8no8/PIIS2589-7500(26)X2008-8
Effectiveness of app-based interventions for glucose management, cardiometabolic and mental health, and related risk factors: an umbrella review with meta-analysis
Maria F Vasiloglou, PhDa Send email to maria.vasiloglou@rd.nestle.com ∙ Evangelia Kotzakioulafi, MSca ∙ Fabio Mainardi, PhDa ∙ Mavra Ahmed, PhDb,c ∙ Amanda E Staiano, PhDd ∙ Eirini Dimidi, PhDe ∙ et al.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00032-4/fulltext?dgcid=raven_jbs_etoc_feature_landig
Prediction of structural glaucoma progression from baseline fundus photographs using deep learning: a retrospective multicentre study
Ruben Hemelings, PhDa,b,c Send email to ruben.hemelings@seri.com.sg ∙ Damon W Wong, PhDa,b ∙ Jacqueline Chua, PhDa,d ∙ Jan Van Eijgen, PhDc,e ∙ João Barbosa-Breda, PhDc,f,g ∙ Adèle Ehongo, PhDh ∙ et al.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00055-5/fulltext?dgcid=raven_jbs_etoc_feature_landig
FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia?utm_medium=email&utm_source=govdelivery
FDA Approves Imaavy (nipocalimab-aahu) for Warm Autoimmune Hemolytic Anemia
The U.S. Food and Drug Administration has approved a new indication for Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older with inadequate response to corticosteroids or immunosuppressive therapy. Imaavy was previously approved for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
wAIHA is a condition in which the immune system mistakenly targets and destroys the body's own red blood cells, leading to anemia that can range from mild to severe and life-threatening. Like gMG, wAIHA is driven by harmful IgG autoantibodies.
Imaavy is a targeted therapy that works by blocking a protein in the body called the neonatal Fc receptor (FcRn), which normally keeps those disease-causing antibodies circulating in the blood. By blocking this receptor, Imaavy speeds up the removal of those harmful antibodies, helping to reduce the damage they cause.
Imaavy is administered as an intravenous infusion. The approval was granted to Janssen Biotech, Inc.
For more information visit: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia
Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations October 14, 2026
https://www.fda.gov/drugs/news-events-human-drugs/navigating-fda-bayesian-draft-guidance-design-analysis-and-review-considerations-10142026?utm_medium=email&utm_source=govdelivery
Join SBIA for its Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations! This webinar will provide an in-depth overview of FDA's January 2026 draft guidance on the use of Bayesian methodology in clinical trials of drug and biological products, a PDUFA VII commitment, and its implications for trial design and analysis.
You should attend if you’re a clinical trial, regulatory science and regulatory affairs professional working on clinical trials and studies where Bayesian methods can potentially be used as an alternative statistical approach. Such uses are most beneficial in settings where it is appropriate to leverage information from previous studies or use adaptive designs. The most common settings include pediatric and rare disease trials.
FDA experts will walk through guidance topics including success criteria and operating characteristics in Bayesian trials, considerations for prior distributions, missing data and estimands in a Bayesian framework, documentation and reporting expectations, and more.
If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.
FDA READI-Home Innovation Challenge: Reducing Readmissions through Device Innovation for the Home
https://www.fda.gov/medical-devices/home-health-care-hub/fda-readi-home-innovation-challenge-reducing-readmissions-through-device-innovation-home?utm_medium=email&utm_source=govdelivery
FDA Announces Initial Participants Selected for READI-Home Innovation Challenge
The FDA has selected initial participants to advance to the interaction phase of the READI-Home Innovation Challenge, an effort to accelerate patient access to home use medical device technologies that may help reduce hospital readmissions.
Participants selected to advance to the interaction phase of the Innovation Challenge will receive:
Early engagement with the FDA through sprint discussions.
More frequent interactions and feedback to help refine device design and/or relevant testing for home use indications.
An opportunity to demonstrate their technology at the FDA’s research facilities.
These selections represent an important step in advancing innovative technologies for care at home after an acute hospital stay. The FDA intends to update the list as additional participants are selected. Submissions will continue to be accepted through September 30, 2026.
Questions?
If you have questions about this Innovation Challenge, please refer to our Frequently Asked Questions or email HealthHomeHub@fda.hhs.gov with the subject line “READI-Home Innovation Challenge Inquiry.”
Bacteria share proteins to survive antibiotics
Bacteria share proteins to survive antibiotics
At a Glance
Researchers found that some bacteria share proteins that help others survive antibiotics.
The study suggests a novel approach that may help treat persistent bacterial infections.
https://www.nih.gov/news-events/nih-research-matters/bacteria-share-proteins-survive-antibiotics
Immune cells cross blood-brain barrier during human aging
Immune cells cross blood-brain barrier during human aging
At a Glance
Researchers found that some of the brain’s immune cells are replaced by immune cells from bone marrow as people age.
The findings suggest that scientists might one day be able to use immune cells born outside the brain to deliver therapies for brain disorders.
https://www.nih.gov/news-events/nih-research-matters/immune-cells-cross-blood-brain-barrier-during-human-aging
DNA organization changes in Alzheimer’s disease, aging
DNA organization changes in Alzheimer’s disease, aging
At a Glance
New research showed the 3D organization of DNA in cells changes in Alzheimer’s disease and aging.
The results suggest the changes may contribute to altered gene activity observed in Alzheimer’s and aging.
https://www.nih.gov/news-events/nih-research-matters/dna-organization-changes-alzheimers-disease-aging
Coating stops tooth decay in children
Coating stops tooth decay in children
At a Glance
A clinical trial found that a topical treatment called silver diamine fluoride stops cavities in young children from getting worse.
The simple treatment could prevent surgery and other serious consequences for children with severe tooth decay.
https://www.nih.gov/news-events/nih-research-matters/coating-stops-tooth-decay-children
Dementia-free years may decrease with smoking, hypertension, and diabetes
Dementia-free years may decrease with smoking, hypertension, and diabetes
At a Glance
Researchers found that smoking, high blood pressure, and diabetes in midlife lower the number of years a person is likely to live without dementia.
The findings could help guide behavior and lifestyle changes to prevent dementia.
https://www.nih.gov/news-events/nih-research-matters/dementia-free-years-may-decrease-smoking-hypertension-diabetes
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
https://clinicaltrials.gov/study/NCT05406583?utm_medium=email&utm_source=govdelivery
FDA Approves Drug to Treat HIV Infection in Newborns
The U.S. Food and Drug Administration (FDA) has approved Tivicay PD tablets for oral suspension (dolutegravir) to treat HIV infection in babies from birth up to four weeks weighing at least 2 kg, in combination with other antiretroviral agents. Tivicay and Tivicay PD were previously approved for adults and children older than four weeks.
Condition
HIV (human immunodeficiency virus) is a virus that attacks the body's immune system, increasing the chances of developing serious infections or cancer and without treatment can lead to AIDS (acquired immunodeficiency syndrome). There is no cure for HIV, but prevention and treatment options are available.
Data Supporting Tivicay PD in Newborns
Data from the IMPAACT 2023 study and pharmacokinetic modeling data supported the application. In this study (NCT05406583), 48 newborns exposed to HIV 1 and weighing at least 2 kg received Tivicay PD from birth for up to six weeks, in combination with standard-of-care antiretroviral medications to prevent mother-to-child HIV transmission. The newborns were followed for 16 weeks. Results showed the drug levels of Tivicay PD in newborns were similar to those associated with efficacy in adults. The drug’s safety profile in newborns was also similar to that observed in older pediatric and adult patients.
Safety Information
Patients should not receive Tivicay or Tivicay PD if they had previous allergic reactions to the drug, or if they are also receiving dofetilide. Serious allergic reactions have been reported. Patients should be monitored for liver damage. Immune resconstitution syndrome has been reported in patients treated with combination antiretroviral therapy.
Taking Tivicay or Tivicay PD with certain other medications may cause the drug to stop working against HIV or lead to serious side effects. Patients or their caregivers should tell their healthcare provider about all medications they are taking before starting Tivicay or Tivicay PD.
Tivicay tablets and Tivicay PD tablets for oral suspension are not substitutable on a milligram-per-milligram basis.
Designations
Tivicay PD received priority review for this population.
martes, 25 de agosto de 2026
Uncovering how obesity leads to Alzheimer’s disease It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis. Written byAllison Whitten, PhD
Uncovering how obesity leads to Alzheimer’s disease
It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/uncovering-how-obesity-leads-to-alzheimer-s-disease-17179?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--Ma_mRbio0_Tb9p1to7Y9ISzL1XmEa_xhjnMoEFiDVDEmPIT-1hTcTtKZhzWoSY1eBl32o4-zZ5EsBrrMU2kBmqtBvTQ&_hsmi=434969664&utm_content=434969664&utm_source=hs_email
The biggest risk factor in the development of Alzheimer’s disease (AD) is one that can’t be controlled: the act of aging itself. But there are other risk factors that lay the groundwork for the disease earlier in life that can be changed — like obesity during midlife. The presence of obesity in middle age can mean up to a 74 percent increased risk of developing dementia, clearly signaling a key relationship between excess adipose tissue and neurodegeneration in the brain. Yet, the biological mechanisms linking the two have remained a mystery.
Can the healthcare system catch up to GLP-1 drug use? Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results. Written byBree Foster, PhD
Can the healthcare system catch up to GLP-1 drug use?
Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/can-the-healthcare-system-catch-up-to-glp-1-drug-use-17108?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9GYVEyXaLMBMj7Xa8j5E3MeIhFDq5KR_VGZf5UT9yQSdPvyz5GI5HW7ZLuuFxg1Sin_w1O_cnWryV1P2aYsWqEITplEA&_hsmi=434969664&utm_content=434969664&utm_source=hs_email
When GLP-1 drugs first entered clinical practice nearly two decades ago, few could have predicted how quickly they would escape the confines of endocrinology and enter everyday conversation. Today, medications like Ozempic and Wegovy are discussed not just in clinics and conferences, but on social media, red carpets, and group chats — often framed as lifestyle enhancers rather than powerful, lifelong medications.
An old small molecule drug could fight obesity and keep lean muscle First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss. Written byAllison Whitten, PhD
An old small molecule drug could fight obesity and keep lean muscle
First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/an-old-small-molecule-drug-could-fight-obesity-and-keep-lean-muscle-17474?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_el91H-YOBZXtKN3rSW1QsRWKG4f_FOW09aYVw97dGYSA0f5DJkZv1qln-AvNYlBOfC8ODfPOF7vQ61WKcRJhKa7Wztw&_hsmi=434969664&utm_content=434969664&utm_source=hs_email
Losing weight can happen via two paths: eating less, or spending more energy. Today’s blockbuster GLP-1 drugs are well-known for their ability to help people eat less, but finding drugs that increase energy expenditure could add another effective option to treat obesity and related metabolic disorders.
FDA drafts roadmap for regulating generative AI medical devices STAT News | August 25, 2026
https://geneticliteracyproject.org/2026/08/25/fda-drafts-roadmap-for-regulating-generative-ai-medical-devices/
The FDA is drafting a first-ever policy roadmap for regulating medical devices powered by generative AI, according to STAT News reporter Mario Aguilar. “Our goal is formal policy guidance,” said Rick Abramson, director of the FDA’s Digital Health Center of Excellence, describing the discussion paper the agency recently released.
CRISPR-edited tomatoes could deliver dramatically higher cold-season yields The Hebrew University of Jerusalem | August 25, 2026
https://geneticliteracyproject.org/2026/08/25/crispr-edited-tomatoes-could-deliver-dramatically-higher-cold-season-yields/
Researchers identify a genetic mechanism that coordinates flower development and fruit formation, paving the way toward tomato varieties with more reliable winter harvests.
FDA-approved mRNA flu vaccine signals future for RNA therapeutics Li Li | August 25, 2026
https://geneticliteracyproject.org/2026/08/25/fda-approved-mrna-flu-vaccine-signals-future-for-rna-therapeutics/
Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often not directly transferable to another.
The story behind Moderna’s cancer vaccine miracle Wall Street Journal | August 25, 2026
https://geneticliteracyproject.org/2026/08/25/the-story-behind-modernas-cancer-vaccine-miracle/
A personalized mRNA shot for melanoma just did something no cancer vaccine has done before. As The Wall Street Journal’s Alex Janin reports, the company’s personalized mRNA cancer vaccine, intismeran autogene, succeeded in a Phase 3 trial for high-risk melanoma patients — the first personalized mRNA cancer therapy to hit its mark in a late-stage study.
What’s the political and health battle over GRAS–ingredients ‘Generally Recognized as Safe’ Chuck Dinerstein | August 25, 2026
https://geneticliteracyproject.org/2026/08/25/whats-the-political-and-health-battle-over-gras-ingredients-generally-recognized-as-safe/
Behind every significant advance in US food safety lies a public health disaster that forced Congress to act. A regulatory carve-out, the GRAS loophole, a long-standing exception intended for harmless pantry staples, remains a pathway that allows food and supplement companies decide for themselves whether new ingredients are safe. The FDA is once again under pressure to rein in GRAS. At stake is how much the public should trust an invisible self-policing system and the forces calling for change.
FDA Approves Multiple Myeloma Treatment, Denies Neuroendocrine Tumors Treatment by CheckRare Staff| Published on: Aug 20, 2026
FDA Approves Multiple Myeloma Treatment, Denies Neuroendocrine Tumors Treatment
by CheckRare Staff| Published on: Aug 20, 2026
https://checkrare.com/fda-approves-multiple-myeloma-treatment-denies-neuroendocrine-tumors-treatment/
Addressing Patient Experiences With IgA Nephropathy by Madaline Spencer| Published on: Aug 24, 2026
Addressing Patient Experiences With IgA Nephropathy
by Madaline Spencer| Published on: Aug 24, 2026
Gaia Coppock, MD, Nephrologist and Associate Professor of Clinical Medicine at the University of Pennsylvania, discusses patient experiences with IgA nephropathy (IgAN).
https://checkrare.com/addressing-patient-experiences-with-iga-nephropathy/
Cancer screening guidelines need to address long-term care facilities I’m a cancer epidemiologist, and my aunt’s recent passing from stage 4 breast cancer led me to reflect on guidelines
https://www.statnews.com/2026/08/25/cancer-screening-guidelines-long-term-care-facilities/
By Kim JohnsonAug. 25, 2026
Johnson is a cancer epidemiologist and professor at Washington University in St. Louis in the Brown School of Social Work.
Certain Blood Transfusions Put Patients At Risk Of Experiencing Symptoms of Alpha-Gal Syndrome, Study Finds +...
Certain Blood Transfusions Put Patients At Risk Of Experiencing Symptoms of Alpha-Gal Syndrome, Study Finds
MedPage Today reported that in regions of the U.S. with a high prevalence of tick-induced alpha-gal syndrome (AGS), researchers found that people with type O blood who received B or AB platelet or plasma units were nearly four times more likely to have an allergic transfusion reaction compared with those who received O units. Researchers said the findings would likely lead to a change in transfusion practices.
https://kffhealthnews.org/morning-breakout/pharma-and-tech-082526/
Study: At Least 25% Of NFL Players Could End Up With Brain Disease
Researchers noted that the rate of actual chronic traumatic encephalopathy, or CTE, is likely higher given that not all players' brains were tested after they died. “I bet the real number is a lot bigger,” said former Tampa Bay Buccaneers center Randy Grimes, who lost two teammates who were found to have had CTE. Scientists hope this information leads to reforms to minimize the disease's occurrence.
https://kffhealthnews.org/morning-briefing/tuesday-august-25-2026/
Dr. Wendy Weber to serve as director of the National Center for Complementary and Integrative Health + +... +... +... +...
Dr. Wendy Weber to serve as director of the National Center for Complementary and Integrative Health
Dr. Wendy Weber
Today, National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., announced that Wendy Weber, N.D., Ph.D., has been selected to serve as director of NIH’s National Center for Complementary and Integrative Health (NCCIH). Since October 2025, Dr. Weber has provided scientific leadership and strategic counsel and contributed to budget oversight to NCCIH as acting deputy director. She began her new role on August 23, 2026.
https://www.nih.gov/news-events/news-releases/dr-wendy-weber-serve-director-national-center-complementary-integrative-health
The National Center for Complementary and Integrative Health (NCCIH) is pleased to announce the selection of Wendy J. Weber, N.D., Ph.D., M.P.H., as the next director of NCCIH, effective August 23, 2026.
“I am genuinely honored to be stepping into this role, and I'm excited about what's ahead,” said Dr. Weber. “I am so excited to take on the leadership for the Center and bring us into the next chapter.”
Dr. Weber has been an instrumental part of NCCIH over the last 17 years. Since October 2025, she served as acting deputy director of NCCIH, providing scientific leadership and strategic counsel during a period of transition. Before this, Dr. Weber served as the branch chief for the Clinical Research in Complementary and Integrative Health Branch in NCCIH’s Division of Extramural Research and was responsible for the oversight of NCCIH-supported clinical trials.
As NCCIH director, Dr. Weber will remain committed to scientific rigor and advancing NCCIH’s programs in pain research and whole person health.
“Her combination of clinical training in naturopathic medicine and doctoral-level research training in epidemiology gives Dr. Weber a rare dual perspective, bridging complementary health practice with rigorous scientific methodology,” said National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D.
Dr. Weber has held a series of increasingly senior leadership roles at NCCIH and brings extensive experience with NIH and NCCIH programs, including the Pain Management Collaboratory, Helping to End Addiction Long-term® Initiative, Science of Behavior Change, and Pragmatic Trials Collaboratory.
Dr. Weber earned an M.P.H. and Ph.D. in epidemiology from the University of Washington and a doctorate
of naturopathic medicine (N.D.) from Bastyr University. Prior to joining NIH, Dr. Weber was a clinician-scientist and associate professor at Bastyr University. As an NCCIH-funded researcher, she was the first naturopathic physician to receive an NIH career development award, which supported her work on botanical interventions.
The Pain Management Collaboratory (PMC)
Closing the Gap between Science and Clinical Practice for Pain Management
https://painmanagementcollaboratory.org/
The Helping to End Addiction Long-term® Initiative
The NIH HEAL Initiative® is an NIH-wide effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management.
https://www.nih.gov/heal
Science of Behavior Change (SOBC)
https://commonfund.nih.gov/behaviorchange
The Science of Behavior Change (SOBC) program used a systematic approach to improve our understanding of the underlying mechanisms that would drive behavior change. Unhealthful behaviors—such as smoking, drug and alcohol abuse, overeating, and a sedentary lifestyle—contribute to negative health outcomes and common diseases. Effective approaches to adopting and maintaining healthy behaviors remain few. Though some interventions may lead to changes in behavior in some people, scientists rarely know how or why they work. SOBC researchers used a scientific method to investigate how and why people adopt and sustain healthy behaviors. SOBC brought together scientists from various disciplines, spanning basic and translational science across different health-related behaviors, to explore how a focus on the mechanisms of behavior change in the development of behavior change interventions could reliably improve health outcomes.
Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials
https://rethinkingclinicaltrials.org/
Welcome to the Living Textbook of pragmatic clinical trials, a collection of knowledge from the NIH Pragmatic Trials Collaboratory. Pragmatic clinical trials present an opportunity to efficiently generate high-quality evidence to inform medical decision-making. However, these trials pose different challenges than traditional clinical trials. The Living Textbook reflects a collection of special considerations and best practices in the design, conduct, and reporting of pragmatic clinical trials.
Beyond cancer: The Right to be Forgotten The Lancet Oncology ++... ++
Beyond cancer: The Right to be Forgotten
The Lancet Oncology
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00399-2/fulltext?dgcid=raven_jbs_etoc_email
Sep 2026
Volume 27Number 9p1057-1192, e403-e439
https://www.thelancet.com/journals/lanonc/issue/vol27no9/PIIS1470-2045(26)X2008-3
Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus
Prof Jean-Michel Hannoun-Levi, MD PhDa Send email to jean-michel.hannoun-levi@nice.unicancer.fr ∙ Prof Julie A Margenthaler, MDb ∙ Bethany Anderson, MD PhDc ∙ Rosa Di Micco, MD PhDd ∙ Prof Douglas W Arthur, MDe ∙ Prof Marianne Aznar, PhDf ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00177-4/abstract?dgcid=raven_jbs_etoc_feature_lanonc
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
Prof Masatoshi Kudo, MD PhDa,* Send email to mkudo@med.kindai.ac.jp ∙ Prof Ghassan K Abou-Alfa, MDb,c,d,* Send email to abou-alg@mskcc.org ∙ Prof Zhenggang Ren, MDe ∙ Prof Jeong Heo, MD PhDf ∙ Prof Riccardo Lencioni, MDg ∙ Yasuaki Arai, MDh ∙ et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00278-0/abstract?dgcid=raven_jbs_etoc_feature_lanonc
Major brain changes that occur around age 50 could impact dementia risk By Melissa Rudy Fox News Published August 25, 2026 7:00am EDT +...
Major brain changes that occur around age 50 could impact dementia risk
https://www.foxnews.com/health
Microglia decline after age 50 as inflammatory blood-derived immune cells infiltrate the hippocampus, potentially driving neuroinflammation and dementia.
Protective immune cells begin to decline and are increasingly replaced by more inflammatory cells in midlife, study finds
Melissa Rudy By Melissa Rudy Fox News
Published August 25, 2026 7:00am EDT
https://www.foxnews.com/health/major-brain-changes-occur-around-age-50-could-impact-dementia-risk
US Cancer Trials Heavily Favor Single Drugs Over Care Issues Medscape Medical News ++++ ++++
US Cancer Trials Heavily Favor Single Drugs Over Care Issues
Medscape Medical News 26 minutes ago
US Cancer Trials Heavily Favor Single Drugs Over Care Issues
Ernie Mundell
https://www.medscape.com/viewarticle/us-cancer-trials-heavily-favor-single-drugs-over-care-issues-2026a1000tjt?src=
Ruxolitinib Reduces Acute GVHD in Transplant Patients
Medscape Medical News 1 hour ago
Low-Dose Ruxolitinib Reduces Acute GVHD After Haploidentical Stem Cell Transplantation
August 25, 2026
https://www.medscape.com/viewarticle/low-dose-ruxolitinib-reduces-acute-gvhd-after-haploidentical-2026a1000tja?src=
Longer Targeted Therapy May Not Raise Cancer Risk in SpA
Medscape Medical News 4 hours ago
Prolonged Targeted Therapy Not Linked to Higher Risk for Cancer in Spondyloarthritis
https://www.medscape.com/viewarticle/prolonged-targeted-therapy-not-linked-higher-risk-cancer-2026a1000ti4?src=
Cardioprotection Rarely Used in Adults With Blood Cancers
Medscape Medical News August 24, 2026
Cardioprotection Rarely Used in Adults With Blood Cancers
Edited by Amy Norton
https://www.medscape.com/viewarticle/cardioprotection-rarely-used-adults-blood-cancers-2026a1000tcp?src=
County-Level Medical Debt Tied to Poorer Cancer Survival
Medscape Medical News 59 minutes ago
County-Level Medical Debt Tied to Poorer Cancer Survival
Edited by Amy Norton
https://www.medscape.com/viewarticle/county-level-medical-debt-tied-poorer-cancer-survival-2026a1000tjp?src=
How Strong Is Antioxidants’ Link to Cervical Cancer Risk?
Medscape Medical News 3 hours ago
How Strong Is Antioxidants’ Link to Cervical Cancer Risk?
Tara Haelle
https://www.medscape.com/viewarticle/how-strong-are-antioxidants-link-cervical-cancer-risk-2026a1000tic?src=
Fixed-Duration Combo Shows Promise for Relapsed MCL
Medscape Medical News 6 hours ago
Fixed-Duration Combo Shows Promise for Relapsed MCL
Edited by Gargi Mukherjee
https://www.medscape.com/viewarticle/fixed-duration-combo-shows-promise-relapsed-mcl-2026a1000th8?src=
Mushrooms Gain Ground in Medicine Despite Limited Evidence
Medscape News Europe August 24, 2026
Mushrooms Gain Ground in Medicine Despite Limited Clinical Evidence
Laurence Salmon
https://www.medscape.com/viewarticle/mushrooms-gain-ground-medicine-despite-limited-clinical-2026a1000tdp?src=
No calorie counting, no smaller portions: the diet change linked to weight loss ynet|08:19
No calorie counting, no smaller portions: the diet change linked to weight loss
A study found that participants on a low-fat vegan diet ate about 491 fewer calories a day and lost an average of 6.4 kg in 16 weeks, without counting calories or cutting portions; so how did it work?
ynet|08:19
https://www.ynetnews.com/health_science/article/hyemet9pgg
lunes, 24 de agosto de 2026
Trump administration has deleted or altered nearly 400 federal datasets on public health, education and safety standards The Guardian | August 24, 2026
https://geneticliteracyproject.org/2026/08/24/trump-administration-has-deleted-or-altered-nearly-400-federal-datasets-on-public-health-education-and-safety-standards/
America’s official data trove is quietly shrinking, and nobody in charge is explaining why. A Guardian investigation by reporters Amy Qin and Flávio Pessoa found that the Trump administration has deleted at least 28 federal datasets and altered 338 more since January 2025, touching public health, education, and safety records across more than 60 agencies.
Medicine stopped shaking hands. We should start again A brief moment of human connection can make a big difference
https://www.statnews.com/2026/08/24/doctors-hand-shakes-patients-research/
By Zain KhawajaAug. 24, 2026
Khawaja is an emergency medicine resident physician at Northwestern University.
Americans bought 12% less soda under new SNAP restrictions, study says SNAP bans on soda and candy are a major talking point of the Make America Healthy Again movement
https://www.statnews.com/2026/08/24/snap-restrictions-12-percent-drop-soda-purchases/
By Sarah ToddAug. 24, 2026
Reporter, Commercial Determinants of Health
Inside Moderna and Merck’s cancer vaccine triumph The drugmakers overcame rampant doubts, logistical challenges, and the pandemic
https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/
By Matthew Herper, Jason Mast, and Angus ChenAug. 24, 2026
Is the Combination of GLP-1s and Clozapine Safe? David Brzostowicki + +++++ +++
https://www.medscape.com/viewarticle/combination-glp-1s-and-clozapine-safe-2026a1000sk0?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
Patients taking clozapine routinely gain as much as 20 or 30 kg, with weight gain being the most common reason cited for discontinuation of the antipsychotic. Until recently, clinicians had little to offer them.
FDA Psychiatry Roundup: Latest Updates
https://www.medscape.com/viewarticle/fda-psychiatry-roundup-july-2026-2026a1000qgu?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
Hidden Health Risks of Borderline Personality Disorder
https://www.medscape.com/viewarticle/hidden-health-risks-borderline-personality-disorder-2026a1000ql0?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
THC Safe, Effective for PTSD-Related Nightmares
https://www.medscape.com/viewarticle/thc-safe-effective-ptsd-related-nightmares-2026a1000rc6?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
No Clear Link Between Semaglutide, Depression
https://www.medscape.com/viewarticle/semaglutide-use-and-risk-depression-show-no-clear-2026a1000s4u?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
Psychiatric Disorders Common in MOGAD
https://www.medscape.com/viewarticle/psychiatric-disorders-common-and-emerge-early-mogad-2026a1000s06?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
MEDSCAPE AI
Clinical questions asked by your peers
Which mechanisms drive cardiovascular risk in BPD?
https://www.medscape.com/ai-search?query=Which%20mechanisms%20drive%20cardiovascular%20risk%20in%20BPD%3F&ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
How do cannabinoids affect PTSD nightmare pathophysiology?
https://www.medscape.com/ai-search?query=How%20do%20cannabinoids%20affect%20PTSD%20nightmare%20pathophysiology%3F&ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
Does semaglutide worsen clozapine-related colonic transit delay?
https://www.medscape.com/ai-search?query=Does%20semaglutide%20worsen%20clozapine-related%20colonic%20transit%20delay%3F&ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986
Why ex vivo CAR T still matters in the age of in vivo hype As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable. Written byBree Foster, PhD
Why ex vivo CAR T still matters in the age of in vivo hype
As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/why-ex-vivo-car-t-still-matters-in-the-age-of-in-vivo-hype-17472
The promise of in vivo CAR T is easy to understand. Instead of removing a patient's cells, engineering them in a manufacturing facility, and returning them to the body, developers are working toward delivering the machinery needed to create CAR T cells directly inside the patient.
When a failed trial isn't a failed drug
A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/when-a-failed-trial-isn-t-a-failed-drug-17431?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--9ymqQTeCqXvQSBNk7-mYIIpdJ6DdkuW3H9ORbkurEIa22v0ufhux8-JXQ-vFQ0uGpbRArvqIeh6orNmzAn-f5FdmOHg&_hsmi=434389976&utm_content=434389976&utm_source=hs_email
When a Phase 3 clinical trial misses its primary endpoint, the outcome is often treated as definitive. The drug failed to demonstrate efficacy, development stops, and the therapy may never be tested again.
But a negative trial in a heterogeneous patient population does not necessarily mean that every participant failed to benefit. It may instead mean that any treatment effect was diluted when patients with very different disease biology and treatment responses were analyzed together.
Intensive Nurse-Led Supportive Care Tied to Better QOL During Palliative Chemotherapy Edited by Sayantani Gupta
https://www.medscape.com/viewarticle/intensive-nurse-led-supportive-care-tied-better-qol-during-2026a1000t9k?src=
Higher nurse-led supportive care intensity (SCI) was associated with greater improvements in quality of life (QOL), symptom burden, coping, and self-management capability among patients with advanced solid tumors who received palliative chemotherapy.
Breast Cancer Survivors: Who Benefits From Weight-Loss Meds? Will Pass + + + +
https://www.medscape.com/viewarticle/breast-cancer-survivors-who-benefits-weight-loss-meds-2026a1000tdj?src=
Preschoolers With Cancer Show Below-Average Motor Function, Muscle Strength at Diagnosis
https://www.medscape.com/viewarticle/preschoolers-cancer-show-below-average-motor-function-muscle-2026a1000tcy?src=
Preschool children newly diagnosed with cancer demonstrated clinically significant impairments in gross motor function, muscle strength, and functional level. More than three-quarters showed below-average or worse performance in locomotion, and 69% scored below average in functional mobility.
Bisphosphonates Tied to Lower Mortality in HR+ Breast Cancer
Edited by Katie Lennon
https://www.medscape.com/viewarticle/bisphosphonates-tied-lower-mortality-hr-breast-cancer-2026a1000t8b?src=
Bisphosphonate (BP) use for at least 1 year after breast cancer diagnosis was associated with reduced all-cause mortality and breast cancer-specific mortality in women with hormone receptor-positive (HR+) breast cancer. Among those with triple-negative breast cancer (TNBC), pre-diagnostic BP use and continued use across both pre- and post-diagnosis periods, on the other hand, were linked to more than tripled recurrence risk and more than doubled breast cancer-specific mortality risk, the new study showed.
Does Maintenance Therapy Improve Survival After First-Line Bevacizumab Treatment in Metastatic Colorectal Cancer?
Edited by Gargi Mukherjee
https://www.medscape.com/viewarticle/does-maintenance-therapy-improve-survival-after-first-line-2026a1000sy8?src=
Maintenance therapy was associated with longer overall survival (OS) than active surveillance in patients with metastatic colorectal cancer (mCRC) who achieved disease control after first-line bevacizumab-based combination chemotherapy. However, this association was not maintained after adjustment for baseline prognostic factors, suggesting that baseline differences may have contributed to the observed survival advantage.
Mushrooms Gain Ground in Medicine Despite Limited Clinical Evidence Laurence Salmon
https://www.medscape.com/viewarticle/mushrooms-gain-ground-medicine-despite-limited-clinical-2026a1000tdp?src=
Mushrooms have attracted growing interest in nutrition and medicine because their bioactive compounds have anticancer, metabolic, anti-inflammatory, antiviral, neuroprotective, and immunomodulatory effects. However, stronger clinical evidence is required.
Are Microplastics Feeding Cancer Risk? David Brzostowicki
https://www.medscape.com/viewarticle/are-microplastics-feeding-cancer-risk-2026a1000tby
Microplastics have been detected in human blood, brain tissue, placentas, and tumors. Federal agencies have committed $144 million to study them. But if patients ask whether microplastics are giving them cancer, the most honest answer may be the least satisfying one: We don’t know, and we’re not close to determining a causal link.
domingo, 23 de agosto de 2026
Digital program reduces anxiety and depression in adults with chronic medical conditions
https://www.news-medical.net/news/20260820/Digital-program-reduces-anxiety-and-depression-in-adults-with-chronic-medical-conditions.aspx
A digital program combining guided movement, breathing and meditation exercises, and coping-skills training reduced anxiety and depression symptoms in adults with chronic medical conditions, according to a new study published August 20th in the open access journal PLOS Medicine by Puneeta Tandon of the University of Alberta, Canada, and colleagues.
Wake-activated brain circuits reveal what drives the urge to sleep
https://www.news-medical.net/news/20260820/Wake-activated-brain-circuits-reveal-what-drives-the-urge-to-sleep.aspx
By mapping the brain during prolonged wakefulness, researchers pinpointed neuronal populations whose activity rises with time awake and tested how strongly they shape the pressure to sleep.
In a recent study published in the journal Nature, researchers conducted comprehensive whole-brain activity mapping and targeted circuit manipulations in mice to elucidate the poorly understood neural mechanisms governing homeostatic sleep drive.
Multifunctional nanoplatform addresses three key barriers to effective TNBC immunotherapy
https://www.news-medical.net/news/20260821/Multifunctional-nanoplatform-addresses-three-key-barriers-to-effective-TNBC-immunotherapy.aspx
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15-20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with limited treatment options. Even immunotherapy - an approach that has transformed cancer treatment - benefits fewer than 20% of TNBC patients, largely because tumors contain large numbers of regulatory T cells (Tregs) that suppress the immune system and prevent it from effectively attacking cancer cells.
PCOS prevalence rises among pregnant women in China
https://www.news-medical.net/news/20260821/PCOS-prevalence-rises-among-pregnant-women-in-China.aspx
Polycystic ovary syndrome (PCOS) affects approximately 6% to 20% of women of reproductive age globally and remains undiagnosed and poorly managed, especially during pregnancy, leading to significant healthcare costs. The economic burden of PCOS was estimated to be $8 billion annually in 2020, with $375 million attributed to pregnancy-related complications. The implementation of China's universal two-child policy has led to an increase in the proportion of advanced-age pregnant women, a greater use of assisted reproductive technologies, and a rise in multiple pregnancy rates, further exacerbating the health risks faced by women with PCOS. However, limited large-scale studies have investigated the prevalence and maternal-fetal outcomes in pregnant women with PCOS. In addition, the impact of China's evolving fertility policies on this population remains largely unclear.
Australian researchers uncover a promising new way to tackle triple-negative breast cancer
https://www.news-medical.net/news/20260821/Australian-researchers-uncover-a-promising-new-way-to-tackle-triple-negative-breast-cancer.aspx
Australian researchers have uncovered a promising new way to tackle one of the most aggressive forms of breast cancer, raising hopes for more effective treatments to stop the disease from spreading.
The study, undertaken by Adelaide University and the Olivia Newton-John Cancer Research Institute, has identified a molecular switch that drives the spread of triple-negative breast cancer (TNBC) – the subtype responsible for some of the poorest outcomes because it lacks the hormone receptors that make many other breast cancers treatable with existing therapies that target these receptors.
Neurogenesis stalls in the brains of adults with major depressive disorder, study shows
https://www.news-medical.net/news/20260821/Neurogenesis-stalls-in-the-brains-of-adults-with-major-depressive-disorder-study-shows.aspx
Most of our brain's 100 billion neurons are created before we're born, but the trickle of neurons created in the adult brain hippocampus could be instrumental in preventing depression, suggest findings from a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons.
Study provides a more nuanced picture of biological mechanisms linked to autism
How does autism manifest in the brain? Researchers from the University of Southern Denmark and Odense University Hospital have investigated this question in a new study involving 60 adults.
https://www.news-medical.net/news/20260821/Study-provides-a-more-nuanced-picture-of-biological-mechanisms-linked-to-autism.aspx
For the first time, they combined three advanced brain-scanning techniques, allowing them to examine the brain's dopamine system, energy use and communication between brain regions at the same time.
Historic redlining continues limiting healthy food access, study finds
Bad housing, high crime and poor schools are more important than transportation or income when it comes to accessing healthy food in neighborhoods historically subjected to "redlining" - the now-illegal practice once used to refuse loans, insurance or mortgages to people in certain neighborhoods that were disproportionately inhabited by racial and ethnicity minorities.
https://www.news-medical.net/news/20260821/Historic-redlining-continues-limiting-healthy-food-access-study-finds.aspx
Only three of 1,357 FDA-cleared AI devices tested patient outcomes
https://www.news-medical.net/news/20260820/Only-three-of-1357-FDA-cleared-AI-devices-tested-patient-outcomes.aspx
Hundreds of AI tools are entering clinical care, but researchers traced how quickly the evidence thins out when the focus shifts from regulatory authorization to trials that measure what actually happens to patients.
A recent study published in the journal PLOS Digital Health found a significant gap between the number of artificial intelligence (AI)-based medical devices cleared or approved by the United States Food and Drug Administration (US FDA) and the number evaluated for patient outcomes.